NCT07736248

Brief Summary

To evaluate the efficacy and safety of genicular artery embolization in patients with symptomatic knee osteoarthritis refractory to conservative treatment.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
25mo left

Started Aug 2026

Typical duration for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 21, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 30, 2026

Completed
2 days until next milestone

Study Start

First participant enrolled

August 1, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2028

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2028

Last Updated

July 30, 2026

Status Verified

July 1, 2026

Enrollment Period

2 years

First QC Date

July 21, 2026

Last Update Submit

July 25, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • change from baseline in visual analog scale (VAS) pain score

    pain intensity measured using the 10-cm visual analog scale (VAS). scores range from 0 to 10, with higher scores indicating greater pain. The change from baseline to 6 months after genicular artery embolization will be assessed.

    Baseline and 6 months after the Procedure

Secondary Outcomes (3)

  • Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score

    Baseline, 3 months, and 6 months after the procedure

  • Change from Baseline in Health-Related Quality of Life Score (EQ-5D-5L)

    Baseline and 6 months after the procedure

  • Technical Success Rate of Genicular Artery Embolization

    During the procedure

Study Arms (1)

genicular artery embolization

EXPERIMENTAL

Participants with symptomatic knee osteoarthritis will undergo super-selective genicular artery embolization using calibrated microspheres. Clinical outcomes will be assessed using pain and functional scores during follow-up.

Other: suerselective angioembolization of genicular artery in symptomatic knee OA

Interventions

Common femoral artery access will be obtained using ultrasound guidance. A 4-Fr or 5-Fr vascular sheath will be inserted. 5 Fr copra catheter or 5 Fr pernst catheters with be used. Diagnostic Angiography Selective angiography of one or more of the following arteries will be performed using microcatheter : * Superior medial genicular artery. * Superior lateral genicular artery. * Inferior medial genicular artery. * Inferior lateral genicular artery. * Descending genicular artery. * Recurrent tibial artery branches. Abnormal findings suggestive of synovial inflammation include: * Hypervascular blush. * Tumor-like neovascularity. * Early venous filling. * Increased periarticular vascularity. Superselective Embolization A microcatheter (1.7-2.4 Fr) will be advanced into target vessels. Embolization will be performed using one of the following agents: * Imipenem/Cilastatin suspension. * Polyvinyl alcohol particles (100-300 μm). * Microspheres (100-300 μm).

genicular artery embolization

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of knee osteoarthritis according to the criteria of the American College of Rheumatology.
  • Radiographic evidence of osteoarthritis corresponding to Kellgren-Lawrence grades I-III.
  • Moderate to severe knee pain for at least 6 months. Visual Analog Scale (VAS) score ≥5.
  • Failure of conservative treatment for at least 3 months including analgesics, non-steroidal anti-inflammatory drugs, physiotherapy, lifestyle modification, or intra-articular injections.

You may not qualify if:

  • Kellgren-Lawrence grade IV osteoarthritis.
  • Previous knee arthroplasty.
  • Inflammatory arthropathies such as rheumatoid arthritis, psoriatic arthritis, or gout.
  • Active local or systemic infection.
  • Severe peripheral arterial disease.
  • Coagulation disorders.
  • Renal insufficiency (raised renal chemistry).
  • Pregnancy.
  • Known allergy to iodinated contrast media.
  • Refuse to provide written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (15)

  • Crawford DC, Miller LE, Block JE. Conservative management of symptomatic knee osteoarthritis: a flawed strategy? Orthop Rev (Pavia). 2013 Feb 22;5(1):e2. doi: 10.4081/or.2013.e2. Print 2013 Feb 22.

    PMID: 23705060BACKGROUND
  • Lyu SR, Chiang JK, Tseng CE. Medial plica in patients with knee osteoarthritis: a histomorphological study. Knee Surg Sports Traumatol Arthrosc. 2010 Jun;18(6):769-76. doi: 10.1007/s00167-009-0946-2. Epub 2009 Oct 14.

  • Bohnsack M, Meier F, Walter GF, Hurschler C, Schmolke S, Wirth CJ, Ruhmann O. Distribution of substance-P nerves inside the infrapatellar fat pad and the adjacent synovial tissue: a neurohistological approach to anterior knee pain syndrome. Arch Orthop Trauma Surg. 2005 Nov;125(9):592-7. doi: 10.1007/s00402-005-0796-4.

  • Walsh DA, Bonnet CS, Turner EL, Wilson D, Situ M, McWilliams DF. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthritis Cartilage. 2007 Jul;15(7):743-51. doi: 10.1016/j.joca.2007.01.020. Epub 2007 Mar 21.

  • Mapp PI, Walsh DA. Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis. Nat Rev Rheumatol. 2012 May 29;8(7):390-8. doi: 10.1038/nrrheum.2012.80.

  • Kurien T, Kerslake RW, Graven-Nielsen T, Arendt-Nielsen L, Auer DP, Edwards K, Scammell BE, Petersen KK. Chronic postoperative pain after total knee arthroplasty: The potential contributions of synovitis, pain sensitization and pain catastrophizing-An explorative study. Eur J Pain. 2022 Oct;26(9):1979-1989. doi: 10.1002/ejp.2018. Epub 2022 Aug 19.

  • Sideris A, Malahias MA, Birch G, Zhong H, Rotundo V, Like BJ, Otero M, Sculco PK, Kirksey M. Identification of biological risk factors for persistent postoperative pain after total knee arthroplasty. Reg Anesth Pain Med. 2022 Mar;47(3):161-166. doi: 10.1136/rapm-2021-102953. Epub 2021 Dec 17.

  • Marsh J, Joshi I, Somerville L, Vasarhelyi E, Lanting B. Health care costs after total knee arthroplasty for satisfied and dissatisfied patients. Can J Surg. 2022 Sep 1;65(5):E562-E566. doi: 10.1503/cjs.006721. Print 2022 Sep-Oct.

  • Hawker GA, Guan J, Croxford R, Coyte PC, Glazier RH, Harvey BJ, Wright JG, Williams JI, Badley EM. A prospective population-based study of the predictors of undergoing total joint arthroplasty. Arthritis Rheum. 2006 Oct;54(10):3212-20. doi: 10.1002/art.22146.

  • Ashraf S, Wibberley H, Mapp PI, Hill R, Wilson D, Walsh DA. Increased vascular penetration and nerve growth in the meniscus: a potential source of pain in osteoarthritis. Ann Rheum Dis. 2011 Mar;70(3):523-9. doi: 10.1136/ard.2010.137844. Epub 2010 Nov 15.

  • Pap T, Distler O. Linking angiogenesis to bone destruction in arthritis. Arthritis Rheum. 2005 May;52(5):1346-8. doi: 10.1002/art.21015. No abstract available.

  • Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford). 2005 Jan;44(1):7-16. doi: 10.1093/rheumatology/keh344. Epub 2004 Aug 3.

  • Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013 Jan;21(1):16-21. doi: 10.1016/j.joca.2012.11.012. Epub 2012 Nov 27.

  • Palazzo C, Ravaud JF, Papelard A, Ravaud P, Poiraudeau S. The burden of musculoskeletal conditions. PLoS One. 2014 Mar 4;9(3):e90633. doi: 10.1371/journal.pone.0090633. eCollection 2014.

  • Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults--United States, 2005. MMWR Morb Mortal Wkly Rep. 2009 May 1;58(16):421-6.

Study Officials

  • Moustafa Hashim Mahmoud

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Rehab Awad Mohamed

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

July 21, 2026

First Posted

July 30, 2026

Study Start

August 1, 2026

Primary Completion (Estimated)

August 1, 2028

Study Completion (Estimated)

September 1, 2028

Last Updated

July 30, 2026

Record last verified: 2026-07